Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

ClinicalTrials.gov ID: NCT03264989

Public ClinicalTrials.gov record NCT03264989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis

Study identification

NCT ID
NCT03264989
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
57 participants

Conditions and interventions

Interventions

  • crizanlizumab Drug

Drug

Eligibility (public fields only)

Age range
16 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 18, 2017
Primary completion
Jun 25, 2023
Completion
Jun 25, 2023
Last update posted
Oct 8, 2024

2017 – 2023

United States locations

U.S. sites
12
U.S. states
7
U.S. cities
12
Facility City State ZIP Site status
Novartis Investigative Site Orange Florida 32763
Novartis Investigative Site Tampa Florida 33606
Childrens Healthcare of Atlanta . Atlanta Georgia 30342
Augusta University Georgia Patient Treatment Augusta Georgia 30912
University of Maryland Medical Ctr Baltimore Maryland 21201
Childrens Hospital at Montefiore The Bronx New York 10467
Duke University Medical Center Patient Treatment Durham North Carolina 27710
East Carolina University East Carolina University Greenville North Carolina 27858
Childrens Hospital Of Philadelphia Patient Treatment Philadelphia Pennsylvania 19104-4399
Medical Uni of South Carolina Medical Univ of SC Charleston South Carolina 29425
M Francisco Gonzalez MD PA . Columbia South Carolina 29203
Carolina Blood and Cancer Care of South Carolina Rock Hill South Carolina 29732

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03264989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 8, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03264989 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →